Omico

05/09/2025

✨A revolution is underway in cancer care. Genomics and precision oncology are transforming how people can be treated.

Omico’s campaign to help people know their options in this new era has been named a finalist in the 2025 PRIME Awards — awards that recognise the best in healthcare communications and initiatives. This recognition is shared with our creative partners Cube Public Relations and Orchard, who helped bring this awareness campaign (social media, podcasts, webinars) to life.

We’ve also been shortlisted for our science-led work in matching people to the personalised, precision therapies most likely to work for them based on their unique cancer.

This recognition helps us build more understanding about precision oncology across the community. Thank you PRIME Awards Australia.

Congratulations to all finalists!

04/09/2025

💛 We couldn’t agree more.

This , we’re giving a big shout-out to our close partner Children's Cancer Institute and to our colleagues leading the Childhood Cancer Program.

Their work is bringing precision oncology to every child diagnosed with cancer — a vision we share for all Australians, no matter their age or postcode.



UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute Rare Cancers Australia Love Your Sister

September is Childhood Cancer Awareness Month, a time for us to honour all children diagnosed with cancer - and acknowledge the enormous impact childhood cancer has on children, their families, and the community.

At Children's Cancer Institute, we believe a life should be long. That every child should get the chance to grow up, plan exciting futures, and live a life that is full of possibilities.

But sadly, cancer cuts life short for hundreds of children every year, before they've even had a chance to make their mark. In Australia alone, more than 1000 children and adolescents are diagnosed with cancer every single year. And every week, three young lives will be lost to the disease.

For over 40 years, Children’s Cancer Institute has been conducting research into the causes, prevention and cure of childhood cancer - and we have made extraordinary progress. In the 1960s cancer was practically a death sentence in children, today, more than eight out of 10 children survive. But we won't stop until every child can live a long, happy and healthy life.

So, if you share our belief that a life should be long, join us this September for Childhood Cancer Awareness Month and Donate Your Age. That's $1 for every year that you have been lucky enough to live.

Donate Your Age not just about giving, it's a chance to feel grateful for every precious year of life you've been given, while supporting the research that will one day find a cure for every child with cancer.

A life should be long.

Donate today at https://ccia.support/CC25FB

01/09/2025

🌼 Spring has sprung in Canberra — and so has . We’re looking forward to an inspiring day ahead.

01/09/2025

30,000 Australians, leaving no stone unturned.

Over 30,000 people have now been referred to Omico’s programs.

Most of these people are living with advanced or hard-to-treat cancers — where treatment options are limited — and have had the chance for precision oncology to uncover new options, and new hope.

By pinpointing genetic changes in a tumour that are driving its growth, comprehensive genomic profiling (CGP) can open doors to possibilities — including matches to personalised, precision treatments or clinical trials. Potential life-extending solutions that would otherwise be unknown.

If you or someone you love is facing cancer, ask your oncologist whether CGP, free through Omico’s free Cancer Screening Program (CaSP), may be appropriate.

👉 Talk to your oncologist or visit our website to learn more: https://www.omico.com.au/patients-and-families/



Cancer Institute NSW Children's Cancer Institute Rare Cancers Australia Love Your Sister

28/08/2025

❓Am I eligible for Omico’s Cancer Screening Program (CaSP)?

Omico’s CaSP provides free Comprehensive Genomic Profiling (CGP) for Australians with less survivable cancers. This test looks at the unique features of a cancer, to help identify potential matches to new personalised, precision therapies and clinical trials.

To participate in (CaSP), you must:
✅ Be aged 16 years and older (children and adolescents may be eligible through the ZERO Childhood Cancer Program);
✅ Have a solid-tumour cancer which is advanced, incurable or has a poor prognosis (meaning a low chance of being cured or controlled by treatment);
✅ Be Medicare eligible.

For full details about the inclusion criteria, please download our CaSP General Information Sheet:https://www.omico.com.au/wp-content/uploads/2024/03/CaSP-General-Information-Sheet_V1.4-CLEAN-1.pdf

More than 30,000 Australians have already been referred to Omico’s programs, giving them access to advanced genomic testing and the possibility of being matched to precision treatments and clinical trials that may not otherwise be available. We encourage you to talk to your cancer doctor (oncologist) to understand if CaSP may be appropriate for you.

Learn more:
🔗 Patient information booklet: https://bit.ly/3XHYdTk
🔗 FAQ Booklet: https://bit.ly/47cbREg

27/08/2025

A 3-minute explainer with MBC Action Australia + Omico: what genomic profiling is, and why it matters for people facing metastatic cancer.

🎙️ In the latest episode, Associate Professor Mandy Ballinger from Omico joins Jen Byles, to share how can help people .

Comprehensive genomic profiling (CGP) looks closely at the unique features of a person’s cancer, helping doctors match patients to precision treatments or clinical trials that may be right for them - this is what precision oncology is all about.

“Genomic profiling really has the potential to uncover information that hasn’t been known about the particular features of that patient’s tumour before, which then allows for further treatment options.” —Associate professor Mandy Ballinger.

Together with patient advocacy groups like MBC Action Australia, Omico is determined to make sure no stone is left unturned for people facing advanced cancers. Everyone deserves to .

👇 Watch the 3-minute video below.

👉Download our patient information booklet: https://bit.ly/3XHYdTk

27/08/2025

🧬 Today is Inherited Cancer Awareness Day in Australia.

Each year, around 16,500 Australians are diagnosed with inherited cancer. We acknowledge the researchers, clinicians, industry partners, and trial participants driving innovation in inherited cancer care — helping deliver earlier detection, better prevention, and more personalised treatment.

At Omico, our research in this space includes:
🔹 + — surveillance in multi-organ cancer prone syndromes https://www.omico.com.au/our-programs/surveillance-study-in-multi-organ-cancer-prone-syndromes-smoc/
🔹 — genetic cancer risk in the young https://www.omico.com.au/our-programs/genetic-cancer-risk-in-the-young-risc-study/

These programs use advances in precision oncology and genomics to better understand inherited cancer risk and shape future care.

For resources and support for Australians and families affected by inherited cancer, visit Inherited Cancer Australia: https://www.inheritedcancers.org.au/home



Inherited Cancers Australia UNSW Medicine & Health UNSW Cancer Institute NSW Children's Cancer Institute Rare Cancers Australia

22/08/2025

Traditionally, cancer treatment is chosen based on where the cancer started (for example, breast, lung, or bowel) and how it looks under the microscope.

goes further. It uses a test called comprehensive genomic profiling (CGP), which analyses cancer cells to identify any gene changes in them that are driving the cancer to grow. This gives doctors additional information to help them:
✅ Match the cancer to a treatment designed to target those changes to slow or stop the cancer from growing – precise and personalised
✅ Connect patients to new therapies through clinical trials
✅ Reduce unnecessary side effects by avoiding less effective treatments

Precision oncology is a proven, cutting edge and rapidly evolving approach— already helping many people today. It’s not yet routine care in Australia, which is why Omico’s programs provide access to those who need it most, while we continue to advocate for it to become standard care for everyone.

Learn more:
🔗 Download our patient information booklet: https://bit.ly/3XHYdTk
🔗 Download our FAQ Booklet: https://bit.ly/47cbREg

15/08/2025

✨ What is Omico?

Omico is the Australian Genomic Cancer Medicine Centre — helping Australians access cutting-edge cancer care.

We are changing the way we fight cancer through increasing access to precision oncology and improving health outcomes for Australians with cancer.

Through our Cancer Screening Program (CaSP), we provide free Comprehensive Genomic Profiling (CGP) to people with advanced, incurable or poor-prognosis cancer — so they can potentially be matched to precision treatments and clinical trials that are tailored to their unique cancer.

More than 25,000 Australians have already taken part in our programs — referred by cancer specialists from hospitals and clinics across the country. This reflects that CGP and precision oncology are seen as important tools in cancer care. We want to make sure that people who could benefit don’t miss out.

Learn more:
🔗 Download our patient information booklet: https://bit.ly/3XHYdTk
🔗 Download our FAQ Booklet: https://bit.ly/47cbREg

14/08/2025

💙 Rare Cancers Australia continues to support those facing extra challenges — offering comfort and connection to people living with cancer and the carers who stand beside them.

👇 Feel free to share with anyone who could use a listening ear, has questions, or is looking to build a stronger support network.

When you’re diagnosed with cancer, it’s normal to want to connect with other people who understand.

That can be hard when you have a rare cancer, and people with similar experiences can be tricky to find on your own.

That’s where our support groups come in, bringing together people who have similar experiences with cancer – creating communities of people who can relate to each other.

Each group is facilitated by a Specialist Cancer Navigator, and there are even groups for carers, and our Mummy’s Wish group for mums with cancer and young children.

If you’re interested in joining one of our support groups, head to: https://bit.ly/3HlFUPh

14/08/2025

How long does the comprehensive genomic profiling (CGP) process take?

It typically takes 8–10 weeks from the day you have given written consent to take part, to your referring doctor receiving the results and recommendations in a report from the Omico Molecular Oncology Board (MOB). If your referring doctor flags that your case is urgent, your results will usually be provided in 5–6 weeks.

The MOB is a team of different experts in cancer who work together to carefully review your information and genomic results to identify treatment options matched specifically to your cancer.

If you’d like to learn more about CGP and why it can be helpful for people facing challenging cancers:
🔗 Download our patient information booklet: https://bit.ly/3XHYdTk
🔗 Download our FAQ Booklet: https://bit.ly/47cbREg

13/08/2025

🎥 Behind the scenes of some truly meaningful days…

Last week, we had the privilege of filming our next series of patient stories—powerful accounts from Australians navigating difficult cancer journeys, generously sharing their lived experience to help others .

Through these stories, we hope to show what comprehensive genomic profiling (CGP) and matched therapies can offer—hope, information, and sometimes, access to treatments that may not have been considered otherwise.

We’re deeply grateful to those who open up to share their story. By increasing awareness of , they support others facing cancer, build understanding, spark important conversations—and remind us who we’re here for.

📸 Who and what do you see here?
Image 1: Filming of Marina
Image 2: Filming of Jason and his wife Vanessa
Image 3: Filming of Jason and Samuel Johnson
Image 4: The team behind the scenes – Omico and Cube

Stay tuned—something special is coming soon. 💙



Love Your Sister UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute Rare Cancers Australia